Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 615
- Registration Number
- NCT01525641
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site 4, Muroran,Hokkaido, Japan
🇯🇵Boehringer Ingelheim Investigational Site 52, Nanao,Ishikawa, Japan
🇯🇵Boehringer Ingelheim Investigational Site 40, Chuo,Tokyo, Japan
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: tenofovirDrug: tolbutamideDrug: BI 207127Drug: midazolamDrug: caffeineDrug: BI 201335Drug: pegylated interferonDrug: ribavirin
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT01525628
- Locations
- 🇺🇸
1241.27.0006 Boehringer Ingelheim Investigational Site, La Mesa, California, United States
🇺🇸1241.27.0003 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸1241.27.0004 Boehringer Ingelheim Investigational Site, Marlton, New Jersey, United States
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
- Conditions
- HIV Infections
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 398
- Registration Number
- NCT01524900
- Locations
- 🇷🇴
Boehringer Ingelheim Investigational Site 50, Bacau, Romania
🇦🇹Boehringer Ingelheim Investigational Site 6, Graz, Austria
🇦🇹Boehringer Ingelheim Investigational Site 1, Vienna, Austria
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 795
- Registration Number
- NCT01523587
- Locations
- 🇭🇺
Pulmonology Institute of Veszprem County, Farkasgyepu, Farkasgyepü, Hungary
🇮🇳Sri Ramachandra Medical College & Research Institute, Chennai, India
🇮🇳B. P .Poddar Hospital & Medical Research Ltd., Kolkata, West Bengal, India
Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 316
- Registration Number
- NCT01512979
- Locations
- 🇺🇸
1218.83.11022 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇺🇸1218.83.11013 Boehringer Ingelheim Investigational Site, Jacksonville, North Carolina, United States
🇺🇸1218.83.11017 Boehringer Ingelheim Investigational Site, Chattanooga, Tennessee, United States
Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: BI 655064Drug: Placebo to BI 655064
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT01510782
- Locations
- 🇩🇪
1293.1.1 Boehringer Ingelheim Investigational Site, Berlin, Germany
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses
- Conditions
- Healthy
- Interventions
- Drug: BI 409306Drug: Placebo
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 83
- Registration Number
- NCT01505894
- Locations
- 🇩🇪
1289.2.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany
Follow on Study From RE-ALIGN
- Conditions
- Heart Valve ProsthesisThromboembolism
- Interventions
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 158
- Registration Number
- NCT01505881
- Locations
- 🇨🇦
1160.138.11009 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada
🇨🇦1160.138.11001 Boehringer Ingelheim Investigational Site, Saint John, New Brunswick, Canada
🇨🇦1160.138.11012 Boehringer Ingelheim Investigational Site, Newmarket, Ontario, Canada
Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 193
- Registration Number
- NCT01505491
- Locations
- 🇳🇿
1297.1.002 Boehringer Ingelheim Investigational Site, Auckland, New Zealand
🇳🇿1297.1.001 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand
Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: BI 409306Drug: Placebo
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT01493570
- Locations
- 🇧🇪
1289.3.1 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium